Irbesartan Accord

Irbesartan, the active ingredient in Irbesartan Accord, is a Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It treats high blood pressure and helps protect kidney function in patients with diabetic kidney disease. GNH USA supplies Irbesartan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan belongs to the class of Angiotensin II receptor blockers and is used to manage conditions related to the renin‑angiotensin system. Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.

Irbesartan is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after the first dose. - Headache: mild to moderate intensity, often transient. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach, sometimes accompanied by mild abdominal discomfort.

Serious or Rare Side Effects: - Angioedema: rapid swelling of the face, lips, tongue, or throat requiring emergency care. - Renal impairment: worsening kidney function, indicated by rising serum creatinine. - Hyperkalemia: elevated blood potassium levels that may cause cardiac arrhythmias. - Hepatic injury: signs of liver dysfunction such as jaundice or elevated liver enzymes.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor relevant parameters. - Blood pressure monitoring: check regularly to ensure therapeutic response and avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR at baseline and during treatment. - Serum potassium: monitor for hyperkalemia, especially when combined with potassium‑sparing agents. - Pregnancy: avoid use in pregnancy due to risk of fetal toxicity; contraindicated in the second and third trimesters. - Hepatic impairment: use with caution in patients with liver disease, adjusting dose if necessary. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can increase risk of renal dysfunction, hyperkalemia, and hypotension. - Dual blockade with ACE inhibitors or other ARBs: may cause excessive potassium rise and kidney injury. - Potassium‑sparing diuretics (e.g., spironolactone): heightened risk of hyperkalemia. - Lithium: concurrent use can raise lithium concentrations, leading to toxicity. - NSAIDs (high‑dose or chronic): may impair renal function and blunt antihypertensive effect.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - Cyclosporine: can increase serum creatinine; renal function should be closely observed.